11 research outputs found

    Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis

    No full text
    When combined with mesalazine enema, prolonged-release mesalazine once-daily 4 g is as effective and well tolerated as 2 g twice-daily for inducing remission in patients with mild-to-moderately active ulcerative colitis (Clinicaltrials.gov: NCT00737789)

    Modeling of defects, dopant diffusion and clustering in silicon

    No full text

    The lymphocyte-epithelial-bacterial interface

    No full text

    2D and 3D finite element meshing and remeshing

    No full text
    corecore